Cathie Wood’s ARK sells AMD stock, buys SpaceX and X-Energy

Oil prices surged after US attacks on Iran over Hormuz shipping, adding a geopolitical risk premium. In parallel, Cathie Wood’s ARK ETFs reported portfolio reshuffles: ARK bought 607,567 shares of X-Energy (XE) for $11.13M, added 44,196 shares of SpaceX-related exposure (SPCX) for $7.09M, and bought Eli Lilly (LLY) for $7.63M, while trimming AMD ($4.78M), BioNTech (BNTX, $4.16M), Illumina (ILMN) and Natera (NTRA) for about $5.96M combined—signaling a shift within biotech/genomics and a tilt toward space/healthcare.

Analysis

The clean market read is not the oil print itself, but the inflation impulse it creates: higher energy prices raise breakeven inflation and keep real yields sticky, which is poison for long-duration, cash-flow-light equities. That is why the ARK tape matters — the basket is rotating away from the weakest funding stories in genomics/semis and toward the few names with either defensive earnings power or optionality that does not depend on cheap capital. In practice, that means the first-order beneficiary is energy, but the second-order beneficiaries are balance-sheet strength and pricing power, not just "growth".

The bigger loser set is anything with leverage to consumer fuel spend, discretionary demand, and multiple support from low rates. Semis like AMD can absorb a brief risk-off move, but if oil stays elevated for 1-3 months and inflation expectations reprice, the market will start discounting a slower Fed path and a worse terminal multiple for the whole high-duration complex. On the healthcare side, LLY is the kind of name investors hide in when they want growth without funding risk; that rotation can persist even if biotech beta remains weak.

Contrarian view: the market may be overpricing the persistence of the disruption. Maritime chokepoint scares often produce a sharp first move in crude, then fade once escorts, rerouting, and diplomacy restore flow; if that happens, the better trade is to fade the energy squeeze and buy back oversold duration. The structural signal only becomes durable if Brent holds above the high-$80s to $90 area for weeks, because then you get real earnings downgrades, not just headline volatility.

Key Decisions for Investors

• Tactically long XLE or USO vs short ARKK for 2-6 weeks; this is a cleaner expression of higher inflation/real-yield pressure than shorting any single biotech name. Fails if Brent retraces quickly below the shock level or shipping-risk premiums normalize within days.
• Relative-value healthcare: long LLY / short XBI or IBB over 1-3 months. The thesis is that capital will keep migrating toward profitable, self-funding healthcare while cash-burning genomics remains valuation-fragile. Falsify if LLY guidance/margin execution disappoints or if biotech financing conditions improve materially.
• Do not chase the first energy spike blindly; wait for confirmation in crude time spreads and tanker/freight rates before adding to long energy. If those measures fail to tighten, fade the move rather than buy it.
• Watch AMD on any bounce rather than shorting immediately: if the stock cannot reclaim its pre-shock relative strength while rates and oil stay elevated, it becomes a candidate for a short against QQQ over 1-3 months.